EUVIMEDEUVIMED entdecken
Crossref

Risk factors of rituximab‐induced thrombocytopenia in patients with autoimmune bullous diseases

Sang Gyun Lee iD, Soo-Chan Kim iD, Jong Hoon Kim iD

The Journal of Dermatology · 2024

DOI: 10.1111/1346-8138.17006 ↗

Kurz gefasst

Fachartikel in der Zeitschrift The Journal of Dermatology, 2024. Verfasst von Sang Gyun Lee und 2 weiteren Autor:innen. Beteiligte Einrichtung: Department of Dermatology, Gangnam Severance Hospital, Cutaneous Biology Research Institute, Yonsei University College of Medicine, Seoul, Korea. Hauptthemen laut MEDLINE: Thrombocytopenia, Lymphoma, Follicular, Autoimmune Diseases, Arthritis, Rheumatoid. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 11 Literaturangaben. Gefördert von: National Research Foundation of Korea.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Rituximab has been the mainstay treatment for autoimmune bullous diseases (AIBDs). Among the side effects of rituximab, rituximab‐induced thrombocytopenia (RIT) is a rare but critical complication. However, there have been no reports or identification of risk factors for RIT in patients with AIBD. In our retrospective study, we compared rituximab‐treated AIBD in patients with and without thrombocytopenia to explore the risk factors. In addition, we compared two different rituximab protocols (rheumatoid arthritis [RA] and lymphoma) in terms of the incidence and severity of thrombocytopenia. A total of 222 patients were enrolled, and 46 patients (20.7%) developed RIT. Multivariate logistic regression analysis identified age and chronic kidney disease (CKD) as significant factors for RIT. We also found that patients treated with the lymphoma protocol demonstrated a significantly higher mean post‐rituximab platelet count compared with those on the RA protocol. This was the first analysis, to our knowledge, of risk factors for RIT in patients with AIBD. Individuals aged 70 or older and those with multiple comorbidities, particularly CKD, should be closely monitored for thrombocytopenia. For patients with CKD, it may be safer to use the lymphoma protocol for rituximab administration as it results in a lesser reduction in post‐rituximab platelet count.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

ThrombocytopeniaLymphoma, FollicularAutoimmune DiseasesArthritis, RheumatoidSkin Diseases, VesiculobullousRenal Insufficiency, ChronicHumansRituximabRetrospective StudiesRisk Factors

Stichwörter der Autor:innen

autoimmune bullous diseaserituximabthrombocytopenia

Substanzen

Rituximab

Autor:innen und Institutionen

  • Department of Dermatology, Gangnam Severance Hospital, Cutaneous Biology Research Institute, Yonsei University College of Medicine, Seoul, Korea.
  • Department of Dermatology, Yongin Severance Hospital, Cutaneous Biology Research Institute, Yonsei University College of Medicine, Yongin, Korea.

ORCID-Profile: Sang Gyun Lee, Soo-Chan Kim, Jong Hoon Kim

Förderung

  • National Research Foundation of Korea

Zitieren

APA

Lee, S. G., Kim, S. C., & Kim, J. H. (2024). Risk factors of rituximab‐induced thrombocytopenia in patients with autoimmune bullous diseases. The Journal of Dermatology. https://doi.org/10.1111/1346-8138.17006

Vancouver

Lee SG, Kim SC, Kim JH. Risk factors of rituximab‐induced thrombocytopenia in patients with autoimmune bullous diseases. The Journal of Dermatology. 2024. doi:10.1111/1346-8138.17006

BibTeX
@article{Lee2024,
  author = {Lee, Sang Gyun and Kim, Soo-Chan and Kim, Jong Hoon},
  title = {Risk factors of rituximab‐induced thrombocytopenia in patients with autoimmune bullous diseases},
  journal = {The Journal of Dermatology},
  year = {2024},
  doi = {10.1111/1346-8138.17006}
}
Kostenlos starten →